{
	"l1liv0yeText": "Study Design",
	"l1liv0yfText": "Brintellix® 20 mg  has a comparable<br>tolerability profile to 10 mg<span class=\"fs4 v2\">1</span>",
	"l1liv0yqText": "Brintellix® ",
	"l1liv0yrText": "10–20 mg/day (n=100)",
	"l1liv0ysText": "BRIN",
	"l1liv0ytText": "10 mg/",
	"l1liv0yuText": "day",
	"Brintellix_NewAss_7c6c3036c": "<span style=\"color: rgb(77, 127, 134); font-family: '2_TKMNLA+AvenirNextLTPro-Bold';\"><font style=\"font-size: 25px;\">References</font></span>",
	"Brintellix_NewAss_776fd33fe": "<font style=\"font-size: 15px; font-family: '1_EUSBJE+AvenirNextLTPro-Demi'; color: rgb(100, 94, 94);\"><b>1.</b></font> <font style=\"font-size: 15px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular';color: rgb(100, 94, 94);\">Christensen MC et al. CNS Spectr. 2021 Oct 18;1-26. doi:10.1017/S1092852921000936.</font>",
	"Brintellix_NewAss_9ccd52984": "<font style=\"color:#645e5e; font-size:21px; font-family: '1_EUSBJE+AvenirNextLTPro-Demi';\">Meta-analysis of six short-term, fixed-dose, placebo-controlled studies</font>",
	"Brintellix_NewAss_9bdf91438": "<div style=\"text-align:center; color:#645e5e; font-size:17px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular';\">Most frequent TEAE (≥4%; Days 8-56)<sup style=\"font-size:50%;\">‡</sup></div>",
	"Brintellix_NewAss_904a6f326": "<div style=\"text-align:center; color:#645e5e; font-size:12px; font-family: '1_EUSBJE+AvenirNextLTPro-Demi';\">AE incidence (%)</div>",
	"Brintellix_NewAss_9e2d0e0d2": "<div style=\"text-align:center; color:#645e5e; font-size:15px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular';\">Nausea</div>",
	"Brintellix_NewAss_9939d8697": "<div style=\"text-align:center; color:#645e5e; font-size:15px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular';\">Headache</div>",
	"Brintellix_NewAss_9aac8a453": "<div style=\"text-align:center; color:#645e5e; font-size:15px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular';\">Nasopharyngitis</div>",
	"Brintellix_NewAss_903e432f5": "<div style=\"text-align:center; color:#645e5e; font-size:15px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular';\">Dizziness</div>",
	"Brintellix_NewAss_9629b5110": "<div style=\"text-align:center; color:#645e5e; font-size:15px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular';\">Diarrhoea</div>",
	"Brintellix_NewAss_9f7f86c25": "<div style=\"color:#c0c2c7; font-size:9px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular';\">Placebo (n=982)</div>",
	"Brintellix_NewAss_9bb10d765": "<div style=\"color:#569099; font-size:9px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular';\">Brintellix<sup style=\"font-size:50%;\">®</sup> 10 mg (n=633)</div>",
	"Brintellix_NewAss_9770ff191": "<div style=\"color:#cd66cc; font-size:9px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular';\">Brintellix<sup style=\"font-size:50%;\">®</sup> 15 mg (n=298)</div>",
	"Brintellix_NewAss_97595ec37": "<div style=\"color:#5f6a72; font-size:9px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular';\">Brintellix<sup style=\"font-size:50%;\">®</sup> 20 mg (n= 975)</div>",
	"Brintellix_NewAss_9ee3be231": "<div style=\"color:#f28700; font-size:15px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; text-align:center; line-height:1;\">Brintellix<sup style=\"font-size:50%;\">®</sup><br>may be increased to<br>20 mg after<br>Week 1 without<br>compromising<br>tolerability<sup style=\"font-size:50%;\">1</sup></div>",
	"Brintellix_NewAss_9a79fef6c": "<div style=\"color:#646162; font-size:20px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular'; text-indent:-15px; margin-bottom:50px;\"><b style=\"color:#f28700; font-family: '2_TKMNLA+AvenirNextLTPro-Bold'; font-size:25px;\">•</b> In this meta-analysis, no clinically relevent increase in the incidence of TEAEs is seen<br>in patients whose dosage was increased to Brintellix<sup style=\"font-size:50%;\">®</sup> 20 mg after their first week of<br>treatment with 10 mg<sup style=\"font-size:50%;\">1</sup></div>",
	"Brintellix_NewAss_95c32d638": "<div style=\"color:#5f6a72; font-size:11px; font-family: '5_SCCHXC+AvenirNextLTPro-Regular';\">\n<sup style=\"font-size:50%;\">‡</sup>Only TEAEs with an incidence of ≥4% occurring in at least one treatment group are presented. In these fixed-dose studies, patients who were<br>assigned to receive vortioxetine 20 mg received a 10 mg dose for the first week of the 8-week study</div>"
}
